The Chief Medical Officer of RepliCel Life Sciences (REPCF) is Selling Shares


Today, the Chief Medical Officer of RepliCel Life Sciences (REPCF), Rolf Hoffmann, sold shares of REPCF for $3,386.

See today’s analyst top recommended stocks >>

REPCF’s market cap is $6.1 million and the company has a P/E ratio of -3.30.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

RepliCel Life Sciences, Inc. operates as a regenerative medicine company. The company focuses on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function. Its products includes RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin, and pattern baldness. The company was founded on April 24, 1967 and is headquartered in Vancouver, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts